Evidence map›Paper›PMID 29286555›Full record

Trial reportPediatric blood & cancer2018

Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study.

Bryan J Dicken, Deborah F Billmire, Mark Krailo, Caihong Xia, Furqan Shaikh, John W Cullen, Thomas A Olson, Farzana Pashankar, Marcio H Malogolowkin, James F Amatruda and 5 more

Abstract readClinical TrialComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatric blood & cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Bryan J DickenStollery Children's Hospital, University of Alberta Hospital, Edmonton, Alberta, Canada.ORCID 0000-0001-5058-5973
Deborah F BillmireRiley Hospital for Children, Indianapolis, Indiana.
Mark KrailoKeck School of Medicine, University of Southern California, Los Angeles, California.
Caihong XiaKeck School of Medicine, University of Southern California, Los Angeles, California.
Furqan ShaikhThe Hospital for Sick Children, Toronto, Ontario, Canada.
John W CullenRocky Mountain Hospital for Children-Presbyterian St Luke's Medical Center, Denver, Colorado.
Thomas A OlsonChildren's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
Farzana PashankarYale University, New Haven, Connecticut.
Marcio H MalogolowkinUniversity of California Davis, Davis, California.
James F AmatrudaUniversity of Texas Southwestern Medical Center, Dallas, Texas.
Frederick J RescorlaRiley Hospital for Children, Indianapolis, Indiana.
Rachel A EglerRainbow Babies and Children's Hospital, Cleveland, Ohio.
Jonathan H RossRainbow Babies and Children's Hospital, Cleveland, Ohio.
Carlos Rodriguez-GalindoSt. Jude Children's Research Hospital, Memphis, Tennessee.
A Lindsay FrazierDana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

purposeIn this report, we characterize the timing and behavior of malignant ovarian germ cell tumors (GCTs) in pediatric patients with dysgenetic gonads compared to those with normal gonadal development. PATIENTS AND

methodsPatients from the Children's Oncology Group AGCT0132 with malignant ovarian GCTs were included. Within this population, we sought to identify patients with gonadoblastoma, streak ovaries, or other evidence of gonadal dysgenesis (GD). Patients with malignant GCTs containing one or more of the following histologies-yolk sac tumor, embryonal carcinoma, or choriocarcinoma-were included. Patients were compared with respect to event-free survival (EFS) and overall survival (OS).

resultsNine patients with GD, including seven with gonadoblastoma (mean age, 9.3 years), were compared to 100 non-GD patients (mean age, 12.1 years). The estimated 3-year EFS for patients with GD was 66.7% (95% CI 28.2-87.8%) and for non-GD patients was 88.8% (95% CI 80.2-93.8%). The estimated 3-year OS for patients with GD was 87.5% (95% CI 38.7-98.1%) and for non-GD patients was 97.6% (95% CI of 90.6-99.4%).

conclusionPatients presenting with nongerminomatous malignant ovarian GCTs in the context of GD have a higher rate of events and death than counterparts with normal gonads. These findings emphasize the importance of noting a contralateral streak ovary or gonadoblastoma at histology for any ovarian GCT and support the recommendation for early bilateral gonadectomy in patients known to have GD with Y chromosome material. In contrast to those with pure dysgerminoma, these patients may represent a high-risk group that requires a more aggressive chemotherapy regimen.

Indexed as

AdolescentAdultChildChild, PreschoolDisease-Free SurvivalFemaleGonadal DysgenesisHumansInfantInfant, NewbornNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsSurvival Rategonadal dysgenesismalignant ovarian germ cell tumorpediatric outcome

Identifiers

PMID29286555
PMCPMC6219870

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.